drugset / Trial / NCT06805487

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT06805487 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

Zika virus (ZIKV) is an illness people can get from mosquitoes. The infection is generally mild with symptoms that include a fever, rash, red eyes, and joint pain, though most of those infected have no symptoms. Preventing ZIKV is important because if a pregnant person is infected with ZIKV, it can cause birth defects in their unborn child. The goals of this study are to find out if people who have already been infected with one type of ZIKV can get infected with ZIKV a second time, and to test the ability of the TV003 dengue vaccine to prevent people from getting infected with the ZIKV-SJRP challenge virus.

Timeline

Start
2024-09-24
Primary completion
2025-09-15
Completion
2025-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject TetraVax-DV-TV003 Vaccine 0.5 ml Subcutaneous